Argenx Se · EURONEXT:ARGX
Argenx — 43rd Annual J.P. Morgan Healthcare Conference (January 2025)
30 slides from Argenx's conference presentation, Jan 13, 2025
Slide 1: The Next Wave of Innovation
The Next Wave of Innovation 43rd ANNUAL JP MORGAN HEALTHCARE CONFERENCE JANUARY 13, 2025
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or
Slide 3: We are ALL IN on Innovation
® e are ALL IN on Inno vation argenx*
Slide 4: Innovation has no meaning unless it provides real benefit to patients
Innovation has no meaning unless it provides real benefit to patients 4
Slide 5: VYVGART Builds Foundation of Innovation
VYVGART® Builds Foundation of Innovation Foundational Immune Target FcRn First-in-Class Potential Best-in-Class Fc Fragment Pipeline in a Product Opportunity VYVGART 15 In Development 3 Approved Indications 5 ABDEG Precision IgG Degradation Expansive Development Portfolio
Slide 6: VYVGART is Setting a New Standard for Patients
VYVGART is Setting a New Standard for Patients MG MSE = MG-ADL SCORE of 0 or 1 MG-ADL SCORE ≤ 5 Response rate No/minimal symptoms Meaningful response ECI STAGE A 54% 8/10 CIDP 6 7/10 I feel fantastic! Amazing! My wife keeps telling me to shut up because I am talking too much since I am so excited! I
Slide 7: Financial Strength to Invest in Sustainable Innovation
Financial Strength to Invest in Sustainable Innovation 21 75 131 173 218 269 329 374 398 478 573 737 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 $M Product Net Sales by Quarter $2.2B 2024
Slide 8: 2025 Strategic Priorities
Fuel pipeline growth 2025 Strategic Priorities PFS Launch Expand next wave of innovation 4 New Molecules in Phase 1 8 Reach more patients with VYVGART 10 Phase 3s 10 Phase 2s
Slide 9: Reach More Patients with VYVGART
Reach More Patients with VYVGART 9
Slide 10: PFS to Accelerate VYVGART Growth in MG and CIDP
PFS to Accelerate VYVGART Growth in MG and CIDP PFS PDUFA April 10, 2025 Aiming for Self-Administration 4 Global Decisions on Autoinjector Approval in 2025 2027 Planned Launch 10 Pre-Filled Syringe* Autoinjector* *FPO Application Pending Not FDA Approved *FPO Not FDA Approved
Slide 11: Growing VYVGART Leadership in MG
Growing VYVGART Leadership in MG U.S. Addressable MG Patients Total Addressable Market in 2030 Addressable Market at Launch 17K +11K +7K +25K 60K Seronegative Ocular Growth in Biologics Share of Market Path to 60K Addressable Patients Consistent QoQ growth VYVGART has set a high bar 11 Source: argen
Slide 12: Opportunity To Set New Standard in Ocular MG
Ocular Domain Effect in ADAPT (1) Opportunity To Set New Standard in Ocular MG High Disease Burden Impaired ability to work, drive and participate in social activities High Treatment Burden Frequent chronic, high doses of oral corticosteroids(2) Pioneer and Transform + Strong rationale from ADAPT an
Slide 13: Continued Momentum in CIDP
Continued Momentum in CIDP Patients Physicians Payors ~1,000 Patients on Therapy 90% Lives Covered Majority policies favorable 25% New Prescribers Global Expansion Multiple planned launches in 2025 Majority IVIg-experienced Breadth and depth of prescribers 13
Slide 14: Fuel Pipeline Growth
Fuel Pipeline Growth argenx?
Slide 15: Our Pipeline is Positioned to Fuel Continuous Growth
Investigate/ESR Expand GBS NMOSD MG Crisis MG Steroid Taper CIDP gMG oMG snMG CMS SMA ALS MMN CIDP SJD TED DGF AIE Lead ON SSC DM DM ASyS IMNM AMR LN ITP ITP Other I&I Our Pipeline is Positioned to Fuel Continuous Growth Neuromuscular Rheumatology ARGX-119 Empasiprubart Efgartigimod 15 Prevalence Bu
Slide 16: Empasiprubart is Now a Phase 3 Asset
Empasiprubart is Now a Phase 3 Asset DGF and DM Proof of Concept Studies MMN and CIDP Registrational Studies IgG IgM Mannose sugar C5 C4 C2 C3 CP LP 16 Foundational Immune Target Complement Factor C2 First-in-Class Potential Best-in-Class C2-Specific Antibody Pipeline in a Product Opportunity Empasi
Slide 17: ARDA Study: Transformational Data in MMN
Phase 2 ARDA Study: Transformational Data in MMN Significant Unmet Need Empasiprubart Treated Patients Feel Better than their Best on IVIg Life-Limiting Symptoms Progressive, disabling, asymmetric limb weakness Severe disability in 20% of patients Frequently misdiagnosed as ALS IVIg as only approved
Slide 18: Disrupting Blockbuster Markets
18 Disrupting Blockbuster Markets EMPASSION Study Ongoing EMVIGORATE Study to Begin 1H 2025 CIDP Opportunity to shape CIDP with two argenx medicines MMN Two Head-to-Head Phase 3 Studies with IVIg >400 patients enrolled in iMMersioN natural history study Innovation Builds Markets Today Following simi
Slide 19: ARGX-119 is Now in Proof-of-Concept Studies
ARGX-119 is Now in Proof-of-Concept Studies Foundational Immune Target MuSK First-in-Class Potential Best-in-Class MuSK Agonist Antibody Pipeline in a Product Opportunity ARGX-119 SMA Next Indication CMS and ALS Proof-of-concept Studies P P MuSK SIMPLE Antibody Crucial for Neuromuscular Junction Fun
Slide 20: Expand Next Wave of Innovation
Expand Next Wave of Innovation 20
Slide 21: Phase 1 Molecules in 2025
4 Phase 1 Molecules in 2025 Continued Leadership with Broad Immune System Targets ARGX-213 FcRn ARGX-121 IgA ARGX-220 Target Undisclosed ARGX-109 IL-6 Fc-ABDEGTM Potential for monthly dosing Rapid, deep IgA reduction Best-in-class potency NHance® First-in-class sweeper Convenient dosing Prolonged Ig
Slide 22: Innovation Model Generating World-Class Pipeline
Innovation Model Generating World-Class Pipeline Active IIP Programs 4 PHASE 1 10 Proof of Concept 10 PHASE 3 APPROVED Neuro Target Neuro Target ARGX-213 (FcRn) Lupus Nephritis Seronegative MG Neuro Target Neuro Target ARGX-109 (IL6) AMR Ocular MG Neuro Target Rheum Target ARGX-121 (IgA) Scleroderma
Slide 23: Significant Momentum Ahead
Significant Momentum Ahead Regional PFS Approvals 1H25 PFS FDA, EMA decisions on approval 2H25 PFS Canada, Japan decisions on approval Efgartigimod IVIg Switch CIDP Ph4 Efgartigimod Seronegative MG Ph3 Efgartigimod Lupus Nephritis Ph2 Empasiprubart DGF Ph2 ARGX-119 CMS Ph1b ARGX-109 Ph1 1H26 Efgarti
Slide 24: Strong Growth Trajectory to 50K Patients
Wave 1: TODAY Wave 2 (2026-2027) Wave 3 (2028-2030) TED Myositis oMG snMG Sjogren’s gMG CIDP ITP DM MMN CMS CIDP 50K 24 Strong Growth Trajectory to 50K Patients VYVGART Empasiprubart ARGX-119
Slide 25: Vision 2030
25 Vision 2030 COMMITMENT TO OUR INNOVATION MISSION 5 New Molecules in Phase 3 10 Labeled Indications 50k Patients on Treatment 25
Slide 26: Appendix
Appendix argenx?
Slide 27: Top Autoimmunology Launches
Top 5 Autoimmunology Launches Our Innovation is Now Enabling our Sustainable Future 0 100 200 300 400 500 600 700 800 900 1000 L+0 L+1 L+2 L+3 L+4 L+5 L+6 L+7 L+8 L+9 L+10 L+11 L+12 PRODUCT NET REVENUE (USD, M) QUARTERS POST LAUNCH 27
Slide 28: New Molecules and New Indications
ARGX.213 Product : Presentations @)~ (anti-FoRn) 7 4 a New Indications ARGX-109 . io) (Anti-IL-6) VYVVGART* i 3 ARGX-119 aie) I ce oad New Molecule SMA @ —_(MuSK Agonist) j “oat VYVGART'Hytrulo ARGX-121 © (Anti-IgA) * New Molecule (@)_ New Molecule ) \ ©) _ New Molecule © ARGX-220 £ , 2 ‘ \ Product
Slide 29: This is just the Beginning
This is just the Beginning PHASE 3 STUDIES IN PROGRESS 2025 PROOF OF CONCEPT STUDIES snMG 81K* TED 100K ITP-US 75K Sjogren’s 330K IMNM 6K oMG 81K* ASyS 12K DM 70K LN 40K AMR 8K SSc 87K AIE 45K argenx market research; US prevalence and TAM numbers (except Japan ITP), sn gMG and oMG are in-market expa
Slide 30: Next Wave of Growth for VYVGART
Next Wave of Growth for VYVGART • Anti-Ro/Anti-La AutoAbs • Passive transfer model evidence • IgG reduction associated with improvement Treatment effect across multiple clinical endpoints, consistent with biomarker data CRESS/ESSDAI Steroids/NSISTs Cholinergic agonists Artificial tears • Myositis Au
argenx — 43rd Annual J.P. Morgan Healthcare Conference (January 2025) on 6ix